Skip to main content

Table 1 First-generation phase III pure adjuvant studies of paclitaxel in breast cancer

From: Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer

Study Patients Design Follow up (months) DFS OS
CALGB 9344-INT 08 [14] 3,121 AC × 4 versus AC × 4 → P × 4 69 65% versus 70% (5-year); HR = 0.83, P = 0.0023 77% versus 80% (5-year); HR = 0.82, P = 0.0064
NSABP B-28 [15] 3,060 AC × 4 versus AC × 4 → P × 4 64.6 72% versus 76% (5-year); HR = 0.83, P = 0.006 85% versus 85% (5-year); HR = 0.93, P = 0.46
GEICAM 9906 [16] 1,248 FEC × 6 versus FEC × 4 → wP × 8 66 72.1% versus 78.5% (5-year); HR = 0.74, P = 0.006 87.1% versus 89.9% (5-year); HR = 0.78, P = 0.109
HeCOG 10/97 [17] 604 E × 4 → CMF × 4 versus E × 3 → P × 3 → CMF × 3a 62 68% versus 70% (5-year); P = 0.55 81% versus 84% (5-year); P = 0.38
NCIC CTG MA.21 [18] 2,104 CEF versus AC → P versus dose-dense EC → P 30.4 90.1% (CEF) versus 85% (AC → P) versus 89.5% (dose-dense EC → P) (3-year RFS) AC → P versus CEF: HR = 1.49, P = 0.005 AC → P versus dose-dense EC → P: HR = 1.68, P = 0.0006 Dose-dense EC → P versus CEF: HR = 0.89, P = 0.46 NA
GONO-MIG5 [19] 1,055 CEF × 6 versus ET × 4 98.4 71% versus 70% (5-year); P = 0.8 89% versus 88% (5-year); P = NS
  1. First-generation phase III pure adjuvant studies evaluating the role of paclitaxel in the adjuvant treatment of breast cancer. aSchedule every 2 weeks. →, followed by; DFS, disease-free survival; HR, hazard ratio; NS, not significant; OS, overall survival; A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; P, paclitaxel; w, weekly; RFS, recurrence free survival. NA, not available.